Composite tissue allotransplantation--a new era in plastic surgery?
Composite tissue allotransplantation (CTA) holds great potential for reconstructive surgery. The recent hand transplants have made this a clinical reality. However, concerns about CTA have divided the medical community. The current transplants require life-long immunosuppression, which could place the recipients at risk of serious complications. In addition despite potent immunosuppression, chronic rejection may still negate any early favourable results. This article will outline the clinical experience of CTA, the major problems of the technique and the potential solutions to these problems.
Hettiaratchy
Shehan
S
Division of Plastic Surgery/Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, WACC-453, Boston, MA 02114, USA. shehan_h@hotmail.com
Randolph
Mark A
MA
Petit
François
F
Lee
W P Andrew
WP
Butler
Peter E M
PE
D006084:Graft Rejection; D063987:Hand Transplantation; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007719:Knee Joint / Q000601:surgery; D007830:Larynx / Q000637:transplantation; D009493:Neurosurgery / Q000379:methods / Q000639:trends; D019651:Plastic Surgery Procedures / Q000379:methods* / Q000639:trends; D012307:Risk Factors; D013710:Tendons / Q000637:transplantation; D014184:Transplantation, Homologous / Q000379:methods* / Q000639:trends
D007166:Immunosuppressive Agents